Having trouble accessing articles? Reset your cache.

Aug. 9 Company Quick Takes: Nektar, Novo, Biktarvy, Autolus and more

Nektar tumbles on bempegaldesleukin revelation
Nektar Therapeutics (NASDAQ:NKTR) fell $8.65 (29%) to close at $20.92 after reporting during its 2Q19 earnings call late Thursday that it had connected decreasing responses seen in a trial of bempegaldesleukin/Opdivo combination to a

Read the full 394 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers